Polymer-Encapsulated Drug Coating for Recurrent Stricture Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for strictures and stenoses, such as those induced by radiation or surgical procedures, often require repeated interventions due to refractory or recurring issues, and existing drug-coated devices have limitations in efficacy and safety for conditions like cardiovascular and kidney diseases.
Innovation Solution
Development of polymer-encapsulated drug particles with therapeutic agents, optionally including ionic or zwitterionic additives, applied as a coating on balloon catheters or stents to treat or prevent nonvascular and vascular strictures and stenoses by expanding to contact the affected areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug-coated devices are used, then initial treatment can be provided, but repeated interventions are required due to refractory or recurring strictures and stenoses
Solution Approach 1:
The patent applies preliminary action by pre-encapsulating therapeutic agents within polymer matrices before device deployment. The drug particles are prepared in advance with controlled release properties, ensuring sustained therapy is immediately available upon device placement without requiring subsequent interventions.
Solution Approach 2:
The patent implements continuity of useful action through polymer-encapsulated drug particles that provide sustained and controlled release of therapeutic agents over extended periods. This continuous drug delivery mechanism maintains effective therapeutic levels, preventing recurrence of strictures and stenoses, and eliminating the need for repeated interventions.
2Ease of manufacture
If existing drug-coated devices are used, then treatment can be delivered, but safety and efficacy are limited for cardiovascular and kidney diseases
Solution Approach 1:
The patent employs composite materials by combining polymer encapsulation matrices with therapeutic agents to create polymer-encapsulated drug particles. This composite structure provides both mechanical stability for device manufacturing and controlled release properties for improved safety and efficacy in treating cardiovascular and kidney diseases.
Solution Approach 2:
The patent applies parameter changes by modifying the polymer matrix composition, crosslinking density, and degradation rate to control drug release kinetics. These parameter adjustments optimize both the safety profile and therapeutic efficacy of the device while maintaining ease of manufacture through scalable fabrication processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides sustained and controlled drug release, reducing the need for repeated interventions and improving safety and efficacy in treating various strictures and stenoses across different body lumens.
Implementation Method 1
one or more polymers that encapsulate the therapeutic agent
Implementation Method 2
expanding to contact the affected areas
Data Source
AI summary
Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and/or second additive; or a combination thereof.